Interferon (IFN)-β is among the first-line therapies for multiple sclerosis (MS), however the clinical response varies among individuals, and early identification of responders and non-responders would be of critical importance. Here we show that before treatment circulating lymphocytes of MS patients who will respond to IFN-β have higher mRNA levels for the D1-like dopaminergic receptor (DR) D5 in comparison to cells from those who will not respond. Lymphocyte DR D5 is reduced in MS and IFN-β restores their expression and responsiveness. DR D5 mRNA levels in circulating lymphocytes might represent an early marker of response to IFN-β in MS patients.

Levels of mRNA for dopaminergic receptor D₅ in circulating lymphocytes may be associated with subsequent response to interferon-β in patients with multiple sclerosis

COSENTINO, MARCO;MARINO, FRANCA
2014-01-01

Abstract

Interferon (IFN)-β is among the first-line therapies for multiple sclerosis (MS), however the clinical response varies among individuals, and early identification of responders and non-responders would be of critical importance. Here we show that before treatment circulating lymphocytes of MS patients who will respond to IFN-β have higher mRNA levels for the D1-like dopaminergic receptor (DR) D5 in comparison to cells from those who will not respond. Lymphocyte DR D5 is reduced in MS and IFN-β restores their expression and responsiveness. DR D5 mRNA levels in circulating lymphocytes might represent an early marker of response to IFN-β in MS patients.
2014
Dopaminergic receptors; Interferon beta; Lymphocytes; Multiple sclerosis; Tyrosine hydroxylase; β(2)-Adrenoceptors
Cosentino, Marco; Zaffaroni, M.; Marino, Franca
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2016423
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 16
social impact